Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v4-FR | Version v2-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2019-02-18 | 2019-02-04 |
| Drug Identification Number | 02324571 | 02324571 |
| Brand name | SANDOZ RIVASTIGMINE | SANDOZ RIVASTIGMINE |
| Common or Proper name | RIVASTIGMINE | RIVASTIGMINE |
| Company Name | SANDOZ CANADA INCORPORATED | SANDOZ CANADA INCORPORATED |
| Ingredients | RIVASTIGMINE | RIVASTIGMINE |
| Strength(s) | 3MG | 3MG |
| Dosage form(s) | CAPSULE | CAPSULE |
| Route of administration | ORAL | ORAL |
| Packaging size | 4X14/bl | 4X14/bl |
| ATC code | N06DA | N06DA |
| ATC description | ANTI-DEMENTIA DRUGS | ANTI-DEMENTIA DRUGS |
| Reason for shortage | Requirements related to complying with good manufacturing practices. | Requirements related to complying with good manufacturing practices. |
| Anticipated start date | ||
| Actual start date | 2019-01-23 | 2019-01-23 |
| Estimated end date | 2019-03-04 | 2019-02-25 |
| Actual end date | ||
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | ||
| Health Canada comments |